Production of biopharmaceutical proteins by yeast: Advances through metabolic engineering.

Jens Nielsen

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Production of recombinant proteins for use as pharmaceuticals, so-called biopharmaceuticals, is a multi-billion dollar industry. Many different cell factories are used for the production of biopharmaceuticals, but the yeast Saccharomyces cerevisiae is an important cell factory as it is used for production of several large volume products. Insulin and insulin analogs are by far the dominating biopharmaceuticals produced by yeast, and this will increase as the global insulin market is expected to grow from USD12B in 2011 to more than USD32B by 2018. Other important biopharmaceuticals produced by yeast are human serum albumin, hepatitis vaccines and virus like particles used for vaccination against human papillomavirus. Here is given a brief overview of biopharmaceutical production by yeast and it is discussed how the secretory pathway can be engineered to ensure more efficient protein production. The involvement of directed metabolic engineering through the integration of tools from genetic engineering, systems biology and mathematical modeling, is also discussed.
Original languageEnglish
JournalBioengineered Bugs
Volume4
Issue number4
Pages (from-to)207-211
ISSN1949-1018
DOIs
Publication statusPublished - 2013

Fingerprint Dive into the research topics of 'Production of biopharmaceutical proteins by yeast: Advances through metabolic engineering.'. Together they form a unique fingerprint.

Cite this